Management Approach for Normal Random Glucose with Elevated HbA1c

Initial Assessment

The American Diabetes Association recommends confirming the accuracy of the HbA1c measurement using a method certified by the National Glycohemoglobin Standardization Program (NGSP) and standardized to the Diabetes Control and Complications Trial (DCCT) reference assay 1
Potential causes of falsely elevated HbA1c include hemoglobinopathies, conditions with decreased red cell turnover, and certain medications, according to the American Diabetes Association 1
Additional glycemic testing, such as fasting plasma glucose (FPG) and 2-hour plasma glucose during oral glucose tolerance test (OGTT), should be performed to confirm diagnosis, as recommended by the American Diabetes Association 1

The American Diabetes Association recommends beginning with lifestyle modifications and starting metformin concurrently with lifestyle interventions unless contraindicated for patients with confirmed diabetes diagnosis (HbA1c ≥6.5% with other confirmatory tests) 2, 3
For patients with confirmed diabetes, the American Diabetes Association suggests scheduling follow-up within 2-3 months to assess response, and considering adding a second agent based on patient characteristics and comorbidities if target HbA1c is not achieved 2, 4
The American College of Physicians recommends implementing intensive lifestyle modifications focusing on 5-7% weight loss and 150 minutes/week of moderate physical activity for patients with prediabetes (HbA1c 5.7-6.4%) 5, 6

The American Diabetes Association recommends individualizing HbA1c targets based on duration of diabetes, age and life expectancy, comorbid conditions, risk of hypoglycemia, and patient preferences 6, 7
For patients with chronic kidney disease, the National Kidney Foundation suggests adjusting medication doses and being vigilant about hypoglycemia risk 8

The American Diabetes Association advises against relying solely on HbA1c for diagnosis when conditions affecting red blood cell turnover are present, and avoiding aggressive glycemic control in patients at high risk for hypoglycemia 1, 8
The American Association of Clinical Endocrinologists recommends not delaying treatment intensification when glycemic targets are not met 3, 4